Leading Alzheimer’s Disease Experts Join T3D Therapeutics’ Scientific Advisory Board
- Wednesday, February 12, 2020, 6:31
- Environment
- Add a comment
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2020 /PRNewswire/ — T3D Therapeutics, Inc. (“T3D” ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD), announced today the formation of a new Scientific…
About the Author
adminasapcorp has written 41775 stories on this site.